Clinical testing partner ProterixBio operates a CLIA-certified high-complexity clinical testing lab with expertise in developing and validating quantitative clinical assays for inflammation, immune response, and disease pathways. Sales opportunity: offer collaboration as a clinical testing partner or assay development partner for trials and remote blood collection.

Diagnostics for vulnerable Focus areas include populations with COPD, diabetes, and cardiovascular disease, with development of diagnostic solutions addressing unmet needs in population health and chronic care. Sales angle: position suite of biomarker–based risk stratification tools to health systems and payers targeting these high-need groups.

Biomarker algorithms The company develops algorithms combining blood-based biomarkers to identify individuals at high risk for severe outcomes. Opportunity: provide or license multi-marker panels, data analytics, and integration into electronic health records for risk prediction and triage workflows.

Academic partnerships Rigorous test development through collaborations with leading academic medical centers and validation in large, curated cohorts. Sales strategy: leverage partnerships to co-launch validated assays and expand clinical utility in new disease areas or trial endpoints.

Growth and readiness Recent serology and COVID-19 testing milestones demonstrate scalable assay development and commercialization capabilities. With revenue in the low-to-mid millions and $19M in funding, there is room to pursue expanded commercial agreements, expanded LDT offerings, and contract research for new disease biomarkers.